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Granzyme A (GzmA) is considered a major proapop-
totic protease. We have discovered that GzmA-
induced cell death involves rapid membrane damage
that depends on the synergy between micromolar
concentrations of GzmA and sublytic perforin (PFN).
Ironically, GzmA and GzmB, independent of their
catalytic activity, both mediated this swift necrosis.
Even without PFN, lower concentrations of human
GzmA stimulated monocytic cells to secrete proin-
flammatory cytokines (interleukin-1b [IL-1b], TNFa,
and IL-6) that were blocked by a caspase-1 inhibitor.
Moreover, murine GzmA and GzmA+ cytotoxic T lym-
phocytes (CTLs) induce IL-1b from primary mouse
macrophages, andGzmA/mice resist lipopolysac-
charide-induced toxicity. Thus, the granule secretory
pathway plays an unexpected role in inflammation,
with GzmA acting as an endogenous modulator.
INTRODUCTION
Cytotoxic cells employ two distinct strategies to eliminate
targeted cells: engagement of death receptors and the granule
secretory pathway. Cytotoxic cell granule-mediated cell death
involves perforin (PFN) and a family of granule-associated serine
proteases, termed granzymes (Gzms). Originally described in the
mid 1980s (Masson and Tschopp, 1987), Gzms have been pos-
tulated to play a number of biological roles; they have been
thought to act as death effectors or be involved in extracellular
matrix degradation or viral inactivation (Kramer and Simon, 1987;
Masson and Tschopp, 1987).
The first description of mouse native GzmA (nMuGzmA) as be-
ing a cytotoxic serine protease was published by the Henkart lab,
which showed that treatment of EL-4 target cells with isolated
native nMuGzmA and mouse PFN (nMuPFN) caused substantial
target DNA breakdown (Hayes et al., 1989). Shortly thereafter,
Greenberg and Shi isolated native rat GzmA (nRatGzmA),
observing that the protease could induce apoptosis (DNA frag-
mentation) in the presence of rat PFN (Shi et al., 1992). At the
same time, Shiver et al. reported that transfection of rat baso-
philic leukemia (RBL) cells with both MuGzmA and MuPFN genes720 Immunity 29, 720–733, November 14, 2008 ª2008 Elsevier Inc.endowed the line with the potential to induce target cell DNA
breakdown (Shiver et al., 1992).
Subsequently, GzmB/ mice, which lack GzmB but express
GzmA and PFN, were generated, and the evaluation of antitumor
host defense clearly established that GzmB is critical for granule-
mediated apoptosis in vitro (Heusel et al., 1994). In comparison,
the phenotype of GzmA/ mice was unexpectedly nondescript,
showing that antitumor host defense was not diminished, but
deficits against ectromelia mouse pox virus were noted (Ebnet
et al., 1995; Mullbacher et al., 1996). As a means of reconciling
the apparent inconsistencies, the results for GzmA were attrib-
uted to functional redundancy of the granule proteases.
For verification of the cytotoxic effect of GzmA, recombinant
human GzmA (rHuGzmA) was produced and shown to mediate,
together with rat PFN, a form of cell death that was associated
with prominent membrane damage (Beresford et al., 1999a).
Subsequent studies showed that rHuGzmA, when delivered
with rat PFN, cleaves a number of intracellular substrates, with
the most crucial being disruption of DNA-repair programs (SET
and APE-1) (Beresford et al., 2001; Fan et al., 2003a; Fan et al.,
2003b; Martinvalet et al., 2005; Zhang et al., 2001). Furthermore,
ex vivo cytotoxic T lymphocytes (CTLs) of GzmB(/) mice were
found to induce apoptosis by multiple criteria (Pardo et al., 2004).
Taken together, the data strongly supported the original concept
that GzmA was indeed lethal.
Using nHuGzmA, without contaminating nHuGzmB, and
rHuGzmA, we show here in both short-term cell-death assays
and a long-term proliferative assay that the proteases lack
cytotoxic activity after intracellular delivery with either HuPFN
or Adenoviral particles. Furthermore, evidence indicates that
nMuGzmA and rMuGzmA also fail to induce target cell death
after intracellular delivery. GzmA was only cytotoxic when micro-
molar concentrations were combined with rat PFN, and then the
cells succumbed to necrosis due to virtually instantaneous
membranolysis.
Considering alternate biological functions, we find that
nHuGzmA and rHuGzmA (but not inactive protease) induce
human adherent peripheral blood mononuclear cells (PBMCs)
to express a proinflammatory cytokine profile consisting of inter-
leukin-1b (IL-1b), IL-6, IL-8, and TNF-a. Signaling by HuGzmA
appears to require internalization of the protease rather than
engagement of transmembrane receptors, and the resultant
cytokine expression occurs in the presence of caspase-1 activa-
tion. Taken together, the data suggest that human and murine
GzmA do not directly contribute to cell death. Instead, the
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that may involve components of the recently described cytosolic
pattern-recognition system (Franchi et al., 2006). To our knowl-
edge, GzmA may represent the first description of an endoge-
nous mediator that engages this system to induce expression
of IL-1b, providing an important link between cytotoxic cells
and the innate immune response.
RESULTS
Characterization of Native Human Granzyme A
nHuGzmA was isolated from cytotoxic granules of the NK92
lymphoma cell line with accepted methodology (Hanna et al.,
1993). Immunoblot with GzmA, GzmB, and GzmM antibodies
(Abs) showed that nHuGzmA was not contaminated with
GzmB or GzmM (Figure 1A). The esterolytic activity of nHuGzmA
and rHuGzmA (Axxora) were comparable (Figure 1B) (specific
activity was 120 U/mg for nHuGzmA and 110 U/mg
for rHuGzmA). Finally, the dimeric status of the nHuGzmA was
confirmed by SDS-PAGE and immunoblotting (Figures 1C
and 1D).
To ensure that target cells internalized active nHuGzmA, we
then evaluated the binding and internalization of the labeled pro-
tease. Jurkat cells were treated with increasing concentrations
of nHuGzmA488 for 30 min on ice (binding) (Raja et al., 2005) or
at 37C (internalization). As reported for nHuGzmB (Raja et al.,
2005), the Ka of the dimeric nHuGzmA for Jurkat cells was
approximately 1.0 nM (Figure 1E). nHuGzmA488 was internalized
at all concentrations exceeding the putative Ka (Figure 1F).
Internalization was confirmed by confocal microscopy in which
an endosomal pattern was noted (Figure 1G). To investigate
clearance of nHuGzmA from the cell surface, we conducted
a pulse-wash analysis that showed that more than 70% of the
granzyme was internalized within 5 min (Figure 1H).
nHuGzmA Lacks Cytotoxic Activity with Human
PFN and Adenoviral Particles
Having confirmed that Jurkat cells bind and internalize
nHuGzmA, we examined the cytotoxic potency of the protease
against this cell line as well as other cell lines that are reportedly
sensitive to the effects of the tryptase (Beresford et al., 1999a).
The intracellular delivery of nHuGzmA and nHuGzmB was per-
formed with both HuPFN and Adenoviral particles (AD), with
the latter included for elimination of potentially uncontrollable
effects of PFN (Froelich et al., 2004). After 90 min incubation,
mitochondrial-membrane depolarization, plasma-membrane
permeability, and reactive oxygen species (ROS) generation
were measured. AD effectively delivered nHuGzmB, causing
efficient mitochondrial-potential loss, ROS generation, and
membrane damage. The intracellular delivery of nHuGzmA by
AD, however, was not associated with alteration in these
variables (Figure 2A). Measurement of these parameters after
shorter incubation times (5 min to 60 min) also yielded similar
results (data not shown). When HeLa cells were used as targets,
only AD-mediated delivery of GzmB caused disruption of
mitochondrial-membrane potential or damage to the plasma
membrane (Figure 2B).
Although nHuGzmA appeared to lack cytotoxic activity if
applied to target cells in the presence of AD, it was possiblethat PFN might synergize with the tryptase to kill target cells.
The toxicity of nHuGzmA and rHuGzmA was tested with a cell
line (U937) reportedly susceptible to rHuGzmA in the presence
of rat PFN (Beresford et al., 1999a). For ensuring that an effective
concentration of HuPFN was used to deliver the proteases,
nHuGzmB (1 mg/ml [30 nM]) acted as the positive control. In
comparison to nHuGzmB, nHuGzmA and rHuGzmA were added
to the targets at a 10-fold higher concentration (10 mg/ml; 192 nM
for dimer). Despite the 10-fold higher concentrations, neither
form of HuGzmA altered the mitochondrial-membrane potential
of the U937 cells (Figure 2C).
To confirm that nHuGzmA was noncytotoxic, we determined
the influence of the tryptase on proliferative capacity at 48 hr.
Jurkat cells were treated with described concentrations of
nHuGzmA, rHuGzmA, or nHuGzmB in presence of HuPFN for
3 hr. Then, cells were cultured for 48 hr, and the number of viable
cells was determined. Cells exposed to nHuGzmB and HuPFN
showed a dramatic reduction in viability (20%) at 3 hr and failed
to proliferate (Figure 2D and Figure S1). In comparison, cells
treated with nHuGzmA or rHuGzmA and PFN were viable at
3 hr (>90%; Figure 2D) and appeared to proliferate unhindered
up to 48 hr (Figure 2D and Figure S1).
Nanomolar concentrations of GzmA were used for the
reported experiments. The rationale for this depended on the
following. GzmA is bound and internalized by target cells at
nanomolar concentrations. Furthermore, the delivery agents,
HuPFN and AD, readily deliver GzmB intracellularly at similar
nanomolar concentrations to induce apoptosis. In contrast,
the cytotoxic effect of rHuGzmA has been reported to require
micromolar concentrations of the protease (Beresford et al.,
1999a), as opposed to nanomolar concentrations used for
GzmB-induced apoptosis. The capacity of 1 mM of the native
HuGzmA to induce cell death therefore was evaluated in sepa-
rate experiments with Jurkat and U937 cells. Mitochondrial
depolarization, membrane damage (propidium iodide [PI]
uptake; data not shown), viability at 48 hr (Figure 2E), ssDNA
strand nicks (Figure 2F), and proliferative response at 48 hr (Fig-
ure S1C) showed that Jurkat cells were unaffected by the higher
concentration of the nHuGzmA in the presence of a concentra-
tion of HuPFN that readily delivered GzmB. U937 cells were
similarly resistant (Figure S1Div).
In an effort to strictly verify previous work (Beresford et al.,
1999a), we treated Jurkat cells with rHuGzmA or nHuGzmA
(1 mM) plus rat PFN. Under these conditions, both native and
recombinant HuGzmA appeared to augment the effects of rat
PFN, inducing membrane damage within 5 min of treatment
(Figure 2G), with the recombinant form being more potent.
Depending on the permeabilizing concentration of rat PFN, the
percentage of damaged cells varied from 50% to 100%. We
then discovered that this membranolytic phenomenon occurs
not only with active HuGzmA, but also with nHuGzmB and inac-
tive rHuGzmA (Figure 2H). Employing three different cell lines,
two separate delivery systems, and three short-term parameters
of cell death, as well as a cell-survival assay, we found that
HuGzmA failed to manifest an obvious cytotoxic response in
presence of nHuPFN. In contrast, micromolar concentrations
of the granzyme, either active or inactive, clearly synergized
with rat PFN in vitro to induce Jurkat cell to undergo extremely
rapid necrosis, as opposed to apoptotic cell death.Immunity 29, 720–733, November 14, 2008 ª2008 Elsevier Inc. 721
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(A) nHuGzmA is not contaminated with GzmB or GzmM. Immunoblots of native granzyme A, B, and M (100 ng) were exposed to GzmA (left), GzmB (center), or
GzmM (right) Abs.
(B) nHuGzmA is enzymatically active. Esterolytic activities of the native and recombinant human GzmA were measured at the indicated concentrations with
standard BLT-esterase assay.
(C and D) nHuGzmA is predominantly dimeric. Reduced and nonreduced nHuGzmA were run on 10% SDS-PAGE and silver stained (500 ng per lane). (D) shows
an immunoblot with polyclonal anti-GzmA (100 ng per lane).
(E) nHuGzmA binds to Jurkat cells. Jurkat cells were exposed to nHuGzmA-Alexa 488 at 4C, washed, and sequentially reacted with Rabbit anti-Alexa 488
and donkey anti-rabbit Alexa 488. Mean fluorescence intensity (MFI, geometric mean) of nHuGzmA binding was plotted against the indicated concentrations
(mean ± SD, n = 2). The MFIs (mean ± SD) for autofluorescence and the isotype control were 41.5 ± 0.9 and 41.2 ± 3.0, respectively.
(F) nHuGzmA internalization in Jurkat cells. Targets were incubated with indicated concentrations of nHuGzmA-Alexa 488 for 30 min, washed, and analyzed on
the flow cytometer (MFI ± SD, n = 2).
(G) nHuGzmA internalization in Jurkat cells. Cells were incubated with 38.5 nM of nHuGzmA-Alexa 488 for 30 or 60 min, washed, and analyzed by flow cytometry
(upper panel) or by confocal microscopy (lower panel).
(H) Clearance of nHuGzmA from plasma membrane. Jurkat cells were exposed to 1.92 nM nHuGzmA-Alexa 488 at 4C, washed, and then chased at 37C for
varying times with media. Cells were then sequentially reacted with rabbit anti-Alexa 488 and donkey anti-rabbit Alexa 488. MFI of nHuGzmA binding was plotted
against the time of chase at 37C (MFI ± SD, n = 3).722 Immunity 29, 720–733, November 14, 2008 ª2008 Elsevier Inc.
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with nHuGzmB to Induce Apoptosis?
Although HuGzmA did not appear to be toxic in the presence of
sublytic HuPFN, the tryptase might synergize with GzmB to kill
target cells. Before addressing this question, however, we eval-
uated the joint interaction of the proteases with target cells. We
designed experiments to investigate whether the two Gzms
crosscompete for binding and internalization in our model target
cells. Equivalent or higher concentrations (w/w) of unlabeled
nHuGzmA efficiently blocked binding of nHuGzmB488 to Jurkat
cells (Figure 3A). The binding of nHuGzmA488 then was evaluated
in the presence of unlabelled nHuGzmA, rHuGzmA, and
nHuGzmB (Figure 3B). Here, both native Gzms inhibited binding
at equivalent levels, but recombinant HuGzmA poorly inhibited
nHuGzmA binding. Given the distinct behavior of rHuGzmA,
the interaction of labeled rHuGzmA then was assessed. The
experiments showed that rHuGzmA488 displayed an affinity for
Jurkat cells similar to that displayed by nHuGzmA (Figure 3C),
but the rate and overall amount of internalized rHuGzmA was
substantially less (Figure 3D). The result here suggests that the
two native granzymes share common binding site(s) that differ
for the recombinant protein and that nHuGzmA might potentially
decrease nHuGzmB-induced apoptosis. Considering this
information, we then examined potential synergy (or inhibitory
effects) between nanomolar levels of nHuGzmA and nHuGzmB.
Surprisingly, an excess of nHuGzmA neither increased nor
decreased the magnitude of GzmB-mediated apoptosis in the
presence of HuPFNPFN (Figure 3E).
Is Mouse GzmA Cytotoxic In Vitro?
Given the results for HuGzmA, we asked whether MuGzmA
might also lack cytotoxic activity. The Henkart lab reported
(Hayes et al., 1989) that nMuGzmA, isolated from CTLs, and
MuPFN induced both 51Cr and 3H-thymdine release from murine
target cells. More recently, P. Bird and colleagues observed that
rHuGzmA was not cytotoxic, whereas rMuGzmA and recombi-
nant HuPFN were shown, in preliminary studies, to reduce target
cell survival (Cr release and MTT assays) (Kaiserman et al., 2006).
We therefore examined whether nMuGzmA and rMuGzmA were
cytotoxic in short-term as well as proliferation assays. To pro-
ceed, we had to ensure that MuGzmA expressed high enzymatic
activity. A direct comparison of mouse and human GzmA is not
possible because the proteases have different subsite prefer-
ences (Fruth et al., 1987). However, when tested on a relevant
substrate, both nMuGzmA and rMuGzmA showed comparable
enzymatic activities (nMuGzmA: 37 3 104 U/nM; rMuGzmA:
48 3 104 U/nM) (see Figure S4). Delivering these active prote-
ases into EL-4 cells with SLO did not alter the following parame-
ters: PI, annexin, or ROS (Figures 4A and 4B). Furthermore, the
potential antiproliferative effect of nMuGzmA was examined in
two separate approaches: (1) delivery of nMuGzmA by SLO or
HuPFN into EL-4 cells and measuring cell survival by 3H-Thymi-
dine incorporation (Figure 5A) and (2) treatment of Jurkat cells
with nMuGzmA and HuPFN and measuring cell numbers at
48 hr (Figures 5A and 5B). In both instances, neither nMuGzmA
nor rMuGzmA significantly affected cell viability or suppressed
proliferation of the cell lines. As before, both nHuGzmB and
rMuGzmB were able to kill EL-4 targets and inhibit proliferation.HuGzmA Induces a Discrete Set of Proinflammatory
Cytokines in Adherent Human PBMC
Because HuGzmA appears to lack cytotoxic activity except
under restricted conditions that results in rapid necrosis, what
might be the biologic function(s) of the protease? We had previ-
ously reported that active dimeric nHuGzmA induces expression
of proinflammatory-cytokine genes, primarily in human mono-
cytes (adherent PBMC) (Sower et al., 1996a; Sower et al.,
1996b).
Our first goal was to perform a more detailed analysis to vali-
date the cytokine profile that GzmA induces in monocytes. Using
a multiplex approach, we determined the ability of nHuGzmA to
stimulate 14 cytokines: IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10,
IL-12 (p40 and p70), IL-13, IFN-g, TNF-a, IP-10, and MIP-1b.
Adherent PBMCs were treated with nHuGzmA (10 mg/ml, 192
nM) for 8 hr in the absence of delivery agents. The nHuGzmA
induced secretion of substantial amounts of IL-1b, IL-6, and
TNF-a (Figure 6A) (IL-8 was also induced; data not shown).
Because the cytokine response attributed to nHuGzmA might
be due to endotoxin contamination, we excluded this possibility
by exposing the protease to an EndoTrap matrix designed to
adsorb lipopolysaccharide (LPS). The processed nHuGzmA
stimulated amounts of IL-1b, TNF-a, and IL-6 similar to those
stimulated by untreated protease, indicating that endotoxin con-
tamination was not a critical factor (Figure 6B). To determine
whether cytokine induction required intact enzyme, we evalu-
ated active and inactive rHuGzmA after endotoxin removal.
Only active rHuGzmA induced a cytokine response (Figure 6C).
Comparison of treated and untreated active HuGzmA indicated
that contaminating endotoxin contributed, though only margin-
ally, to the activity of the tryptase (100 pg/ml of endotoxin is
sufficient to induce cytokine secretion by the adherent PBMC;
data not shown).
How GzmA signals cytokine induction is unclear (Sower et al.,
1996a). Putative receptors that bind and internalize the gran-
zymes (e.g., MPR and plasma-membrane-associated HSPGs
and CSPGs) (Motyka et al., 2000; Raja et al., 2005) lack obvious
transmembrane signaling motifs. Although nHuGzmA and
nHuGzmB are internalized, in part, through shared binding site(s)
(see above), only the former appears to induce cytokine expres-
sion (Sower et al., 1996a). The possibility therefore exists that
nHuGzmA requires internalization and release to the cytosol to
signal proinflammatory-cytokine gene expression. We initially
addressed this issue by asking whether dimeric nHuGzmA was
more active than the monomer. The rationale was that the dimer
would be more membranolytic at acidic endosomal pH and thus
released to the cytosol in greater quantities. On a molar basis,
the dimer was indeed four times more active than the monomer
(Figure 7A). For further evidence that GzmA signals intracellu-
larly, rHuGzmA-TAT was expressed, depleted of endotoxin,
and added to adherent PBMC. Recombinant HuGzmA-TAT in-
duced a marked increase in both IL-b and TNF-a expression,
suggesting that granzyme likely signals within the cytosol to in-
duce the proinflammatory cytokines (Figure 7B).
Because nHuGzmA appears to differentially induce IL-1b, IL-6,
and TNF-a in adherent PBMC after cytosolic entry, we specu-
lated that the tryptase might modulate intracellular pathogen-rec-
ognition systems. Three main families of pathogen-recognition
molecules cooperate in host defense: TLRs, nucleotide-bindingImmunity 29, 720–733, November 14, 2008 ª2008 Elsevier Inc. 723
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(A) Jurkat cells were treated with the nHuGzmB or nHuGzmA plus AD for 90 min. Cells were split, and the following were assessed: mitochondrial-potential loss,
ROS generation, and cell viability (mean ± SD, n = 3).724 Immunity 29, 720–733, November 14, 2008 ª2008 Elsevier Inc.
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noid acid-inducible gene-1 receptors. The NLRs, in turn, can
be divided into two distinct pathways that act through
peptidoglycan molecules or muramyl peptides versus IPAF or
Cryopyrin (Franchi et al., 2006). For the latter, a fundamental
upstream signal involves activation of the proinflammatory
caspase-1. Using the specific caspase-1 inhibitor WEHD-FMK
and the pan-caspase inhibitor ZVAD-FMK, we investigated
whether nHuGzmA-mediated induction of IL1-b, TNF-a, and IL-6
was associated with intracellular caspase-1 activation. Native
HuGzmA stimulated adherent PBMC to produce a robust IL-1b,
TNF-a, and IL-6 response that was almost completely blocked
by WEHD-FMK, as well as by the pan-caspase inhibitor (zVAD-
fmk) (Figure 7C).
We then evaluated whether intact cytotoxic cells that selec-
tively secrete GzmA might, together with PFN, induce human ad-
herent PBMC to produce the identified proinflammatory cyto-
kines. To answer this question, we added a NK92 subline
(Maki et al., 2001) to adherent cells in the presence and absence
of EDTA to block granule secretion, and the cytokine response
was determined at 6 hr. The results for this model system sug-
gest that NK92 cells induce the adherent cells to secrete IL-1b
(Figure 7D) and TNF-a (data not shown).
MuGzmA and GzmA from Mouse CTL Induce IL-1b
from Primary Mouse Macrophages
To learn whether the phenomenon observed for HuGzmA was
species specific, we evaluated the cytokine-inducing capacity
of isolated rMuGzmA and CTLs expressing the protease. LPS-
activated, adherent peritoneal macrophages were treated with
rMuGzmA and sublytic SLO or with ATP (Figure 7E, positive con-
trol) for 3 hr. Recombinant MuGzmA delivered by SLO induced
a dose-dependent increase in IL-1b (Figure 7E), whereas inactive
rMuGzmA (PFR-CK pretreated) was ineffective (data not shown).
Next, to learn whether the secretion of IL-1b is also induced by
GzmA positive CTL, we incubated LPS-stimulated adherent
peritoneal macrophages with ex vivo-derived or in vitro-propa-
gated LCMV-immune Gzmb/ CTL ± virus-specific peptide
gp33 for 3 hr. LCMV-immune Gzmb/ CTL specifically induced
IL-1b-release in a dose-dependent manner under the described
conditions (Figure 7E).Biological Relevance of GzmA to a Systemic
Inflammatory Response
To assess the biological relevance of gzmA to inflammatory
processes in vivo, we evaluated the susceptibility of WT and
Gzm-deficient mice to LPS-induced mortality. Compared to
WT mice, Gzma/ mice were more resistant to challenge with
LPS (Figure 7F). Remarkably, Gzmb/ mice manifested greater
resistance, whereas Gzma/Gzmb/ mice were as suscepti-
ble to LPS as WT mice, suggesting that both GzmA and GzmB
contribute to LPS-associated inflammatory processes in vivo.
DISCUSSION
Our unanticipated results suggest that human and mouse GzmA
are not toxic in the presence of vehicles (PFN, AD, and SLO) that
facilitate their intracellular delivery except under very restricted,
nonphysiologic conditions. Instead, active, endotoxin-free
nHuGzmA and rMuGzmA appear to activate the innate immune
response by inducing key proinflammatory cytokines. The cyto-
kine response appears to be relatively selective for monocytic-
like cells, involves cytosolic localization of GzmA, and is induced
by isolated human and mouse GzmA, as well as by human NK
cells and murine CTLs that selectively secrete the granzyme.
Together with the results showing that GzmA contributes to
the lethal effects of LPS, the data strongly support the concept
that the granule-secretion pathway modulates inflammatory
processes as well as mediates cell death.
Since their original description, we have all operated under the
supposition that the granzymes would have cytotoxic activity.
This concept was established for GzmA when MuGzmA and
MuPFN were noted to induce cell death after addition to
suspended target cells (Hayes et al., 1989). In similar work, the
Greenberg lab then reported that isolated nRatGzmA was
cytotoxic in the presence of rat PFN. During cation-exchange
chromatography to isolate the native proteases from cytotoxic
granules, GzmA and GzmB elute sequentially in overlapping
peaks. A sensitive GzmB substrate (or EIA) was not available
to ensure GzmA was free of contaminating GzmB. Thus, the
apparent cytotoxicity of the mouse and rat GzmA might be due
to contamination of the isolated tryptase with coeluted GzmB
(unpublished data).(B) HeLa cells were treated with nHuGzmA (192 nM) or nHuGzmB (31 nM) plus AD for indicated times. Mitochondrial-potential loss or cell viability were
investigated (mean ± SD, n = 3).
(C) U937 cells were treated with nHuGzmA or rHuGzmA (both 192 nM) or nHuGzmB (31 nM) plus PFN (100 ng/ml) for 2 hr at 37C. Cells were stained with
CMX-ROS for evaluation of mitochondrial depolarization (mean ± SD, n = 3).
(D) Jurkat cells were treated with nHuGzmA (384 nM or 192 nM), rHuGzmA (192 nM), or nHuGzmB (31 nM) plus PFN for 3 hr, and cell viability was determined by
trypan blue stain. Cells were then washed and replated for 48 hr, and viability was measured (mean ± SD, n = 3).
(E) The effects of high-dose GzmA on Jurkat cells. Jurkat cells were treated with nHu GzmA (1 mM) or nHuGzmB (31 nM) plus a subpermeabilizing concentration of
nHuPFN (125 ng/ml) for 90 min. Mitochondrial-potential loss was assessed (top panel) at 90 min. A parallel set was incubated for 3 hr, washed, and replated for
48 hr, and viability was measured (bottom panel) (mean ± SD, n = 3).
(F) Jurkat cells were treated with nHu GzmA (1 mM) or nHuGzmB (31 nM) plus a subpermeabilizing concentration of nHuPFN (125 ng/ml) for 180 min, and ssDNA
nicking was determined by flow cytometry (FCM). Cells treated with DNAase (1.25 mg/ml, 20 min at room temperature) served as a positive control. Data are
representative of two independent experiments.
(G) Jurkat cells were treated with either nHu GzmA or rHuGzmA (1 mM) plus subpermeabilizing concentrations of rat PFN (250 and 300 ng/ml) for times ranging
from 5 to 30 min, and membrane damage was determined by PI and FCM. Data are representative of two independent experiments.
(H) Jurkat cells were treated with rat PFN and the described granzyme preparations for times indicated. Propidium iodide was added at the end of the incubation
period, and cells were then analyzed by FCM. PI reactivity is defined as fluorescence activity exceeding 103 units (log scale). Concentration of each granzyme
protein was 1 mM.Immunity 29, 720–733, November 14, 2008 ª2008 Elsevier Inc. 725
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ing GzmA-induced cell cytotoxicity with the combination of
rHuGzmA and rat PFN (Beresford et al., 1999a; Fan et al.,
2003a; Fan et al., 2002; Fan et al., 2003b; Martinvalet et al.,
2005; Zhang et al., 2001; Zhang et al., 2003). We show here
that a mixture of micromolar HuGzmA and rat PFN causes virtu-
ally instantaneous membrane permeabilization, the time frame of
which suggests that the granzyme somehow augments the
membranolytic action of PFN. Notably, active and inactive
rHuGzmA both induce 51Cr release (Beresford et al., 1999a;
see also Beresford et al., 1999b). This observation is consistent
with data here showing active and inactive HuGzmA and active
HuGzmB all induce rapid membrane damage with rat PFN.
How might micromolar amounts of granzyme enhance the
membranolytic effects of PFN? We have observed that limited
concentrations of minimally permeabilizing rat PFN induce
Figure 3. nHuGzmA Competes with nHuGzmB for Binding Sites on Jurkat Cells
(A) Jurkat cells were incubated with nHuGzmB488 (0.78 nM) plus either nHuGzmA or nHuGzmB ranging in concentrations from 0.01- to 20-fold excess (w/w) on ice
for 30 min, followed by measurement of granzyme binding (mean MFI ± SD, n = 2).
(B) Jurkat cells were incubated with nHuGzmA488 (0.48 nM) in the presence of nHuGzmA, nHuGzmB, or rHuGzmA from 0.01- to 20-fold excess (w/w) on ice for
30 min, followed by measurement of granzyme binding (mean MFI ± SD, n = 2).
(C) nHuGzmA and rHuGzmA bind to Jurkat cells with similar affinity. Cells were exposed to either the nHuGzmA488 or the rHuGzmA488 at 4
C, followed by
measurement of granzyme binding (mean MFI ± SD, n = 3).
(D) nHuGzmA is internalized more rapidly than rHuGzmA by Jurkat cells. Targets were incubated with indicated concentrations of nHuGzmA488 or rHuGzmA488 for
the indicated times, washed, and analyzed on the flow cytometer (MFI ± SD, n = 2).
(E) nHuGzmA does not augment nHuGzmB-induced apoptosis. Jurkat cells were incubated with nHuGzmB (1.9 nM to 31 nM) and sublytic concentration of PFN
(25 ng/ml) in the absence or presence of nHuGzmA (19.2 nM) for 90 min at 37C. Mitochondrial-membrane potential was then investigated (representative data for
one of two experiments). Mitochondrial-potential loss in samples treated with nHuGzmA and PFN was 19.3 ± 5 (mean ± SD).726 Immunity 29, 720–733, November 14, 2008 ª2008 Elsevier Inc.
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Granzyme A Modulates Inflammationa subset of low-PI reactive cells (mean fluorescence intensity
[MFI]: 10–100) when PI (10 mg/ml) is added simultaneously with
PFN. This PI uptake, which appears to consist of endocytic
and trans-pore entry of the fluorophore (data not shown), seems
to be a prerequisite for the observed membrane damage pro-
Figure 4. nMuGzmA and rMuGzmA Are Not Cyto-
toxic as Determined by Multiple Parameters
Analyses of apoptotic parameters during nMuGzmA- and
rMuGzmA-induced cell death in EL4 cells. EL4 cells were
incubated with the indicated amounts of protease in the
presence or absence of a sublytic dose of SLO for 4 hr or
were left untreated (control). PS translocation (A; annexin
V staining), membrane damage (A; PI incorporation), and
ROS generation (B) were analyzed by FACS. See table
(inset) for summarized data from three to five experiments.
duced by the micromolar concentrations of
granzyme (data not shown). Comprehensive ti-
tration reveals that restricted amounts of
HuPFN also produce this low-PI reactivity.
Such concentrations synergize with micromolar
concentrations of HuGzmA to enhance mem-
brane damage, indicating that the phenomenon
is not unique to rat PFN (data not shown).
Although the basis for this phenomenon
awaits analysis, we speculate that the density
of the transient pores formed by PFN must
first exceed a critical threshold at which inte-
gral proteins cluster, encouraging increased
focal binding of the granzyme and consequent
membrane disruption. Overall, GzmA does not
manifest cytotoxic activity in vitro except un-
der unique conditions in which relatively high
concentrations of HuGzmA and restricted
concentrations of rat or HuPFN are used. In
this instance, the ensuing cell death is clearly
necrotic and not consistent with CTL-medi-
ated apoptosis in vitro (Goldberg et al.,
1999; Hu and Kipps, 1999). Consequently,
many of the observed biochemical events as-
sociated with GzmA-induced cell cytotoxicity
in vitro may entail the effect of the protease
on dead cells.
The studies involving isolated human and
mouse GzmA seem to contradict data reported
for cytotoxic cells. For example, GzmA+ CTLs
(Gzmb/ mice) kill EL4 cells, albeit with consid-
erably less potency than GzmB+ CTL (Gzma/
mice) (Pardo et al., 2004). This observation
corresponds with earlier work in which the
coexpression of MuGzmA and MuPFN genes
endow RBL cells with the capacity to induce
51Cr release and DNA fragmentation in EL4
cells (Shiver et al., 1992). However, the cyto-
toxic potential of GzmA in CTL and transfected
RBL may not be due to the protease per se,
but depend instead on additional molecules
present in cytoplasmic granules (e.g., other
Gzms and/or cathepsins). In this regard, ex vivo-derived virus-
immune CTL from wild-type and Gzmb/ mice, retrieved at
the peak of their cytotoxic response, express GzmK transcripts
and protein (Pardo et al., 2008; unpublished data). Although
the inconsistencies observed between the cytotoxic activity ofImmunity 29, 720–733, November 14, 2008 ª2008 Elsevier Inc. 727
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logical, further evaluation is necessary for clarification of the
paradoxes.
The data described here support the proposal that the
granule-secretion pathway modulates inflammatory reactions
with GzmA and perhaps other granzymes as key participants.
Whether GzmA contributes to proinflammatory responses as
well as indirectly to cytotoxic responses now merits consider-
ation. Supporting a role in noncytotoxic, antipathogen host
defense is the fact that Gzma(/) mice are known to succumb
to viral pathogens such as ectromelia (Mullbacher et al., 1996).
In this instance, GzmA may trigger virally infected cells to pro-
duce cytokines, attracting phagocytes to clear the infection.
Could GzmA mediate a similar noncytotoxic function in antitu-
mor immunity? In the case of tumor control, secreted GzmA
may induce nonspecific host defense mechanisms, even if the
targets are refractory to CTL-mediated apoptosis. Although our
limited efforts suggest that monocytic cells (Sower et al.,
1996a; Sower et al., 1996b) as well as murine peritoneal macro-
phages are most receptive to the effects of GzmA, it will be
intriguing to learn whether GzmA might also induce tumor
cells to produce bioactive molecules that encourage their elimi-
nation. Thus, the identification of the range of the responsive
cells in both mouse and man requires additional effort, especially
in regards to whether the cytokine-inducing properties of GzmA
contribute indirectly to granule-mediated apoptosis of tumor
cells.
Figure 5. nMuGzmA Is Not Cytotoxic as
Determined Proliferative Assays
(A) Analysis of granzyme cytotoxicity in EL4 cells
by a survival assay. EL4 cells were incubated with
the indicated amounts of nMuGzmA or rMuGzmA
in the presence or absence of a sublytic SLO for
4 hr. After washing, cell survival was monitored
by 3H-thymidine incorporation as described in the
Experimental Procedures. A representative exper-
iment of two independent experiments is shown.
(B) Analyses of nMuGzmA cytotoxicity in Jurkat
cells by 48 hr viability assay. Jurkat cells were
treated with nMuGzmA (384 nM or 192 nM) or
nHuGzmB (31 nM) plus PFN for 3 hr, and cell viabil-
ity was determined by trypan blue stain (top panel).
Cells were then washed and replated for 48 hr, and
viability was measured (bottom panel) (mean ± SD,
n = 3).
Beside the potential host defense ben-
efits of GzmA, the protease could con-
tribute to immunopathology (Simon
et al., 1993). Recent work has shed light
on the role of granzymes in the immuno-
pathology of mCMV infection (van Dom-
melen et al., 2006). PFN/ mice suc-
cumb to inoculated virus, whereas
GzmAxB/ mice survive. Infected PFN-
deficient mice develop the Hemophago-
cytic Syndrome (HS), a state of cytokine
hypersecretion combined with marked
proliferation in T cells and monocytes.
The clinical equivalent of HS occurs commonly in patients with
connective-tissue diseases (Dhote et al., 2003), as well as in
patients who have defects in the granule-secretion pathway (Me-
nasche et al., 2005). Importantly, TNF-blocking Ab attenuated
the intensity of the immunopathology in the PFN/ mice, estab-
lishing a causal role for the cytokine in mediating this hyperactive
inflammatory state. Given that we have not observed a consis-
tently robust induction of proinflammatory cytokines by cells
exposed to GzmB, the results from the Degli-Espoti group (van
Dommelen et al., 2006) suggest that GzmA might contribute to
the development of at least one form of HS.
Although the data indicate that GzmA-mediated cytokine in-
duction is, in part, caspase-1 dependent, the understanding of
the signaling mechanism is highly speculative. Our past efforts
have focused on determining whether GzmA triggers gene
expression via a transmembrane signal. The tryptase, however,
fails to induce Ca influx to efficiently cleave various PAR sub-
types, and it fails to stimulate linked kinase activity (ERK-1)
(data not shown). Tschopp et al. have reported that murine
GzmA directly matures IL-1b, and the processed cytokine is de-
tectable in targets attacked by murine CTLs (Irmler et al., 1995).
We have been unable to reproduce maturation of human IL-1b by
treating lysates of THP-1 cells with nHuGzmA, suggesting the
existence of alternate mechanisms that might be species spe-
cific. The involvement of caspase-1 in GzmA-mediated IL-1b
production offers a vital clue, however, to the mechanism under-
lying signaling by the granzyme. Virtually all the described728 Immunity 29, 720–733, November 14, 2008 ª2008 Elsevier Inc.
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Granzyme A Modulates InflammationFigure 6. nHuGzmA Elicits a Proinflammatory Cytokine Response
(A) Adherent PBMCs were treated with nHuGzmA (192 nM) or LPS (2 mg/ml) for 8 hr at 37C, and supernatants were evaluated in a cytokine multiplex array that
measures 14 cytokines simultaneously. Three cytokines, IL-1b, IL-6, and TNF-a, were upregulated after GzmA treatment. Results are represented as mean ± SD
of three normal donors. p value was determined with a paired Student’s t test.
(B) Endotoxin-free nHuGzmA induces human monocytes to secrete IL-1b, TNF-a, and IL-6. nHuGzmA, depleted of potentially contaminating endotoxin with
EndoTrap matrices, was added to adherent PBMC for 8 hr, and supernatants were assayed for IL-1b, TNF-a, and IL-6. Cytokine concentration for media
control was consistently 0 pg/million cells. For LPS-treated cells, the values for IL-1b, TNF-a, and IL-6 were respectively 40,000 ± 9,000, 28,0000 ± 60,000,
and 195,000 ± 32,000 pg/million cells. (Data represent mean ± SD for three normal donors.)
(C) IL-1b, TNF-a, and IL-6 production in adherent PBMC requires active GzmA. Proteolytically active and inactive rHuGzmA (S195A) and their corresponding
endotoxin-depleted samples were added to adherent PBMCs for 6 hr, and supernatants were assayed for IL1b, TNF-a, and IL-6. Cytokine concentration for
media control was consistently 0 pg/million cells. For LPS-treated cells, the values for IL-1b, TNF-a, and IL-6 were respectively 16,000 ± 9,000, 141,000 ±
7,500, and 115,000 ± 24,000 pg/million cells. (Data represent mean ± SD for three normal donors.)pathways linking caspase-1 and IL-1b involve the phenomenon
of pattern recognition, a multiprotein oligomerization process
that results in the activation of proinflammatory caspases and
IL-1b (e.g., the inflammasome) (Martinon, 2007). The data re-
ported here suggest that GzmA may be an important component
of the granule-secretion pathway linking innate and adaptive
immune responses to inflammatory cascades.
EXPERIMENTAL PROCEDURES
Cell Lines
Jurkat, U937, HeLa, and K562 cells were maintained in complete RPMI media.
NK92 cells (a kind gift from G. Maki, University of Illinois at Chicago) were
grown in Myelocult media (GIBCO Tech). The murine thymoma cell line
EL4.F15 has been described (Pardo et al., 2002).Reagents
nHuGzmA, nHuGzmB, human PFN, and rat PFN were isolated as described
(Froelich et al., 1996; Hanna et al., 1993) (Shi et al., 1992). Recombinant human
GzmA (rHuGzmA) was purchased from Axxora or expressed (Beresford et al.,
1997). Inactive GzmA was generated by site-directed mutagenesis of the
active Ser (Beresford et al., 1997). AD were also used for granzyme delivery
(Metkar et al., 2003). nMuGzmA was isolated from the CTL line 1.3E6SN
(Simon et al., 1986). Recombinant MuGzmA and rMuGzmB were expressed
in E. coli. SLO was kindly provided by S. Bakhdi. The nHuGzmA, nHuGzmB,
and rHuGzmA were labeled with AlexaFluor488 according to the manufac-
turer’s instructions, and esterolytic activity was tested (see Figure S2).
All reagents and tissue culture supplies were purchased from either Sigma
or GIBCO BRL. FITC- and PE-labeled mouse isotype controls, as well as
FITC-CD3, FITC-CD19, and FITC-CD56, were from BD PharMingen. The PE-
labeled CD14 (Beckman Coulter) was a kind gift from R. Pope (Feinberg
School of Medicine, Chicago). Ready gels, silver-stain kit, and Immun-Blot
and Sequi-Blot PVDF membranes were purchased from Bio-Rad. ECLImmunity 29, 720–733, November 14, 2008 ª2008 Elsevier Inc. 729
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Granzyme A Modulates InflammationFigure 7. HuGzmA and MuGzmA Require Intracellular Delivery for Optimal Induction of Cytokine Release
(A) Dimeric nHuGzmA is a more potent inducer of TNFa than monomeric protease. Monocytes were incubated with dimeric and monomeric nHuGzmA for 8 hr at
37C, and supernatants were assayed for TNF-a (mean ± SD of two normal donors).
(B) GzmA-TAT is a more efficient inducer of IL-1b and TNF-a than dimeric nHuGzmA. The GzmA-TAT fusion protein was isolated and depleted of endotoxin. The
GzmA-TAT was 4.31-fold less active than the nHuGzmA by weight. Equivalent concentrations of the nHuGzmA and GzmA-TAT by weight were added to adherent
PBMCs for 8 hr, and supernatants were assayed for IL1b and TNF-a. IL-1b concentration for media and LPS were 0 and 68,000 pg/million cells, respectively.
TNFa level in media and LPS were 0 and 660,000 pg/million cells, respectively. An irrelevant SCR-TAT fusion protein (10 mg/ml, 192 nM equivalent) was used
as a control for the GzmA-TAT protein. It elicited an IL-1b response of 411 pg/million cells and a TNF-a response of 439 pg/million cells. (Data represent one
of two donors.)
(C) nHuGzmA-induced IL-1b, TNF-a, and IL-6 secretion requires caspase-1 activity. Adherent PBMCs were treated with nHuGzmA (192 nM) in media with DMSO
as a vehicle control, with caspase-1 inhibitor (WEHD-FMK, 50 mM), or with the pan-caspase inhibitor ZVAD-FMK (50 mM) for 6 hr at 37C. The supernatants were
assayed for IL-1b, TNF-a, and IL-6 ELISA (mean ± SD of three normal donors). p value was determined with a paired Student’s t test.
(D) NK92 effectors induce adherent PBMCs to secrete IL-1b. NK92 cells were incubated with adherent PBMC targets at 10:1 and 5:1 ratios for 8 hr at 37C in
the presence or absence of EGTA (10 mM). Supernatants were subjected to EIA, with results representative of four donors. The control to assess the possible
influence of EGTA on the adherent cells (nHuGzmA-stimulated cells plus EGTA) showed that the chelator was not directly inhibitory (data not shown).
(E) rMuGzmA induces IL-1b release in primary mouse macrophages. Adherent peritoneal macrophages were incubated with the indicated amounts of
rMuGzmA ± SLO (0.5 mg/ml) or ATP for 3 hr, and supernatants were assayed for IL-1b (mean ± SD). LCMV-immune Gzmb/ CTLs specifically induce IL-1b
release in primary mouse macrophages. Adherent peritoneal macrophages were incubated with LCMV-immune Gzmb/ CTL at 1:1 and 5:1 ± gp33 for 3 hr,
and supernatants were assayed for IL-1b (mean ± SD).730 Immunity 29, 720–733, November 14, 2008 ª2008 Elsevier Inc.
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Biotech.
BLT-Esterase Assay
The esterolytic activities of GzmAs were measured with the Thiobenzyl benzy-
loxycarbonyl-L-lysinate substrate (Hanna et al., 1993).
Immunoblotting
Blotted proteases were probed with anti-GzmA (clone GA-4, 1:1000), anti-
GzmB (clone 2C5, 1:10000, from J. Trapani), or anti-GzmM (clone 4H10,
1:1000, from M. Smyth). The blots were developed with a mouse HRP Ab
(1:1000, Amersham Pharmacia Biotech) and the ECL kit.
Production and Isolation of the rHuGzmA-TAT Fusion Protein
A nine aa sequence from HIV-TAT protein (RKKRRQRRR) (Nagahara et al.,
1998) was added to the C terminus of GzmA with high-fidelity pfu enzyme,
followed by cloning, expression, and isolation as described (Beresford et al.,
1997). A control TAT-Scramblase protein (Biotin-AHA-YGRKKRRQRRR-
SKLACFSHG-CONH2 with TAT sequence underlined) preceded by an amino-
hexanoicacid (AHA) spacer was synthesized by Tufts University core facility.
Both proteins were subjected to endotoxin depletion (see below), and protein
concentrations were determined by Coomassie stain with reduced nHuGzmA
as the standard.
Generation of Monomeric nHu GzmA
Dimeric granzyme was reduced with b-Mercaptoethanol (2-ME, 690 mM) for
30 min at 37C and dialyzed against PBS. Silver staining and immunoblotting
confirmed reduction of the disulfide bonds. The concentration of monomeric
granzyme was determined by Coomassie stain and densitometry with reduced
nHuGzmA that served as an internal standard. Esterolytic activity of the mono-
mer averaged 90% of the original dimer.
Internalization, Binding, and Competition and Clearance assays
Internalization, binding, and competition experiments were done essentially
as described for nHuGzmB (Raja et al., 2005). For confocal microscopy, cells
were allowed to adhere to poly-l-lysine-coated slides, mounted with anti-fade
reagent (Molecular Probes), and imaged with a Nikon C1 microscope system
under 633 magnification. Images were acquired with the Nikon C1 software.
Apoptosis Assays
AD, 200 and 4000 Pfu/cell for Jurkat and HeLa cells, respectively, or huPFN
(permeabilizing <30% cells) acted as granzyme-delivery agents. Mitochon-
drial-potential loss was measured as reported (Metkar et al., 2003). ROS gen-
eration was measured with Hydroxyethidium (2HE, 2 uM) (Martinvalet et al.,
2005). Treatment of cells with hydrogen peroxide served as a positive control
for HE staining. Cell viability was measured with propidium iodide (5–10 mg/ml)
and flow cytometry or by trypan blue and light microscopy.
For studies of mouse Gzms, EL4 cells were incubated with either AD, a
sublytic human PFN, or SLO ± granzymes. After the indicated time frames,
propidium iodide incorporation, annexin V staining, mitochondrial-potential
loss, and ROS production (2HE) were analyzed by fluorescence-activated
cell sorting (FACS) (Metkar et al., 2003; Pardo et al., 2004).
Measurement of ssDNA Strand Nicking by Flow Cytometry
Assay was performed with the Klenow DNA Frag-EL kit according to the
manufacturer’s instructions with one modification. In lieu of the of immunohis-
tochemistry approach, FITC-dUTP and flow cytometry were used to measure
ssDNA nicks. Cells treated with DNAase (1.25 mg/ml) served as positive
controls.Proliferation Assay
Jurkat cells were treated with either nHuGzmA, nHuGzmB, or nMuGzmA in the
presence of PFN for 3 hr at 37C. The cells were washed in Eppendorf tubes,
viability was measured, and cells were replated in RPMI with 10% fetal calf
serum at a density of 1 3 105 cells in 0.5 ml media per well in a 24-well plate.
Cultures were analyzed at 24 or 48 hr for total cell number and viability.
Thymidine Incorporation
El4 cells (1 3 105 cells) were treated with Gzms in the presence or absence of
a sublytic dose of SLO for 4 hr. Cells were then plated in 96-well plates in trip-
licate (200 ml/well), and 0.5 mCi of 3H-thymidine was added to each well. After
12 hr, cells were harvested, and incorporated radioactivity was measured.
Proinflammatory Cytokine Response in Human Adherent PBMC
Human PBMCs were isolated by Ficoll-Hypaque density centrifugation
(Sigma). Monocytes were enriched through plastic adherence (Sower et al.,
1996a); yields consistently represented 10% of input. The adherent cells
were treated with the proteases for 6 to 8 hr at 37C. The supernatants were
collected, and the level of cytokines was measured with a Human Cytokine
Microarray Kit (Allied Biotech). The 14 cytokines detected were IL-1b, IL-2,
IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, IFN-g, IP-10, MIP-1b, TNF-a, IL-12 (p40),
and IL-12 (p70). In other experiments, TNFa, IL1b, and IL6 were quantitated
with ELISA kits from Biosource International (Invitrogen) and R&D Systems.
Use of Caspase Inhibitors
Adherent cells were treated with nHuGzmA in the presence of solvent (DMSO),
a caspase-1-specific inhibitor (Z-WEHD-FMK, 50 mM; R&D systems), or the
pan-caspase inhibitor, ZVAD-FMK (EMD Biosciences) for 6 hr. Supernatants
were assayed for IL-1b, IL-6, and TNF-a by ELISA.
Preparation of Endotoxin-Depleted GzmA
NHuGzmA preparations were subjected to endotoxin removal with the
EndoTrap-Blue kit (Cambrex Biosciences).
Induction of IL-1b Release from Primary Mouse Macrophages
by Isolated Gzm or Ex Vivo-Generated CTL
Adherent thioglycollate-stimulated macrophage from C57BL/6 mice were
prestimulated with LPS (10 ng/ml) for 3 hr. After washing, cells were exposed
to rMuGzmA (±SLO, 0.5 mg/ml) for 3 hr in either basal media or with BSA sup-
plement. For select studies, rMuGzmA was inactivated with PFR-CK for
30 min. LPS-prestimulated adherent primary macrophages were incubated
with ex vivo-derived or in vitro-propagated LCMV-immune gzmB/ CTL ±
LCMV peptide gp33 for 3 hr (Pardo et al., 2008). Supernatants were tested
for IL-b by EIA (Invitrogen). ATP served as positive control.
NK-92-Induced Cytokine Secretion by Human PBMC Adherent Cells
NK92 cells served as effectors, with adherent PBMC serving as targets, in an
8 hr cytotoxicity assay at two effector: target ratios (10:1 and 5:1) in the
presence or absence of EGTA (10 mM). Supernatants were then subjected
to cytokine EIA.
LPS-Induced Mortality in Mice
LPS challenge was carried out with weight- and age-matched C57BL/6 (WT),
GzmA/, GzmB/, and GzmA/GzmB/ mice. Animals were injected
intraperitoneally (i.p.) with 27 mg LPS (Salmonella abortus equi; NG420;
dissolved in PBS) per g body weight. Morbidity and mortality were monitored
every 2 hr through the indicated time period. All animal experiments were
carried out in accordance with the local animal care commission.(F) Differential susceptibility of C57BL/6 (WT), Gzma/, Gzmb/, and Gzma/Gzmb/ mice to high doses of LPS. Age-matched C57BL/6 (eight males),
Gzma/ (four males, four females), Gzmb/ (five males, 3 females), and Gzma/Gzmb/ mice (5 males, 3 females) were injected i.p. with 27 mg of Salmonella
abortus equi-derived LPS/g body weight, and survival was monitored for 48 hr.Immunity 29, 720–733, November 14, 2008 ª2008 Elsevier Inc. 731
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